Personalis Releases Preliminary Revenue for 2024
Personalis, Inc. (Nasdaq: PSNL), a frontrunner in advanced genomics focusing on precision oncology, has unveiled its preliminary revenue figures for the fourth quarter and the entirety of 2024. This announcement signals significant growth in the company's offerings and highlights its ongoing commitment to enhancing cancer management.
Growth in Full Year Revenue
For the full year of 2024, Personalis reports a remarkable revenue of approximately $84.6 million. This figure represents a robust increase of 15% compared to the previous year's revenue of $73.5 million. Notably, this exceeds the company's earlier guidance range of $83.0 to $84.0 million, showcasing the strong performance of Personalis' business operations.
Impact of Pharma Sales on Revenue
The revenue from pharma tests and services, which includes enterprise sales and various other customers, reached approximately $77.2 million in 2024, marking a 20% increase from $64.1 million in 2023. Despite the overall rise in revenue, there was a significant decline in contributions from a key partner, Natera, whose revenue decreased by 20% to about $25.4 million in 2024.
Analysis of Fourth Quarter Results
In the fourth quarter of 2024, Personalis reported preliminary revenue of approximately $16.8 million, down 15% from $19.7 million in the same period in 2023. This decline was primarily influenced by expected drops in revenue from Natera and the U.S. Department of Veterans Affairs Million Veterans Program (VA MVP).
Clinical Testing Volume and Cash Position
The revenue from pharma tests, enterprise sales, and additional customers for Q4 2024 was around $16.6 million, a decrease of 11% compared to $18.7 million in Q4 2023. This includes the forecasted 41% drop in revenue from Natera to approximately $4.2 million. Despite these setbacks, the company's financial position remains robust, with cash, cash equivalents, and short-term investments totaling about $185.0 million by December 31, 2024. This figure notably includes a significant $50 million strategic investment from Merck.
Future Outlook for Personalis
CEO and President Chris Hall emphasized, "In 2024, we achieved nearly 15% growth in annual revenue and made considerable progress towards our objectives for the upcoming year. Our partnership with Moderna and the $50 million investment from Merck signify trust in our technological capabilities and our roadmap to achieving cashflow break-even status."
About Personalis, Inc.
At Personalis, our mission is to revolutionize how cancer is managed through innovative personalized testing. We strive to establish a transformative approach to cancer care, guiding patients from biopsy to long-term management. Our cutting-edge assays integrate tumor and normal profiling with exclusive algorithms, delivering precise insights and adaptive strategies as cancer progresses. Our advanced testing products focus on detecting minimal residual disease (MRD) and recurrence as early as possible, enabling targeted therapy selections based on comprehensive genomic profiling. We are headquartered in Fremont, California, and aim to connect with you on various platforms.
Frequently Asked Questions
What was the revenue reported by Personalis for 2024?
Personalis reported approximately $84.6 million in revenue for the full year of 2024.
How did the revenue from pharma tests and services change in 2024?
The revenue from pharma tests and services increased by 20% in 2024, reaching around $77.2 million.
What were the fourth-quarter revenue figures for Personalis?
The fourth-quarter revenue for Personalis in 2024 was approximately $16.8 million.
What strategic developments has Personalis pursued recently?
Personalis has engaged in a long-term commercial collaboration with Moderna and received a $50 million investment from Merck to support their growth.
How does Personalis aim to manage cancer in the future?
Personalis focuses on advanced personalized testing to guide cancer management, enhancing therapy selection and monitoring disease progression effectively.
